Figure 5.

Effect of STK17B inhibition on T cell activation in vivo. (A) 7 female OT-1 mice (8 weeks of age) were immunized with 10 µg or 3 µg SIINFEKL peptide and dosed with or BLU7482 (200 mg/kg daily, orally in solution formulation (30% HP-β-CD in 100 mM citrate; pH 3). Lymph nodes were collected, single cell suspension was generated by passing through 70 µm mesh filter, and T cell activation was assessed by flow cytometry measuring the expression level of early T cell activation marker CD69. (B) Serum was collected through submandibular vein at 24 hours post treatment, followed by mouse cytokine assay for IL-2 and IFN-γ (Meso Scale Discovery). Representative of n=3 experiments is shown. Statistics: non-parametric T test (GraphPad PRISM). CD, cluster of differentiation; HP-β-CD, 2-hydroxypropyl-β-cyclodextrin; IL-2, interleukin-2; IFN-γ, interferon‐γ; QD, daily; STK, serine/threonine kinase.